[18F FDG PET-Applications in Oncology]

Area of Science:

• Nuclear Medicine
• Oncology
• Radiochemistry

Background:

• Positron Emission Tomography (PET) with 18F FDG is a rapidly growing clinical tool for cancer diagnosis and management.
• FDG-PET demonstrates higher sensitivity and specificity compared to conventional imaging methods like CT, MRI, and ultrasonography for many common cancer types.

Purpose of the Study:

• To detail the indications for 18F FDG-PET in various tumor types.
• To highlight the advantages of FDG-PET in cancer detection, staging, and treatment monitoring.
• To discuss the evolution of PET imaging, including the development of fused PET-CT imaging.

Main Methods:

• Review of clinical applications and indications for 18F FDG-PET in oncology.
• Comparison of FDG-PET performance against conventional imaging modalities.
• Discussion of the role of radiotracer uptake in tumor aggressiveness.

Main Results:

• FDG-PET is effective in detecting a wide range of cancers, with higher uptake correlating with tumor aggressiveness.
• Specific indications include evaluating pulmonary nodules, melanoma recurrence, colon cancer diagnosis, differentiating brain tumors from radiation injury, lymph node assessment, lymphoma staging, and therapy response.
• Fusion imaging (PET-CT) enhances diagnostic accuracy by correlating physiological PET data with anatomical information.

Conclusions:

• 18F FDG-PET is a powerful, non-invasive imaging technique for oncological applications.
• Precise indications are crucial due to the cost of the procedure.
• Future growth is expected with advancements in radiopharmaceuticals and imaging technology.